BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28553961)

  • 1. Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity.
    Nomura K; Klejnot M; Kowalczyk D; Hock AK; Sibbet GJ; Vousden KH; Huang DT
    Nat Struct Mol Biol; 2017 Jul; 24(7):578-587. PubMed ID: 28553961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Catalytic Active but Non-Aggregating MDM2 RING Domain Variant.
    Magnussen HM; Huang DT
    J Mol Biol; 2021 Mar; 433(5):166807. PubMed ID: 33450248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation
    Yang J; Jin A; Han J; Chen X; Zheng J; Zhang Y
    Cancer Res; 2021 Feb; 81(4):898-909. PubMed ID: 33277368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo.
    Saville MK; Sparks A; Xirodimas DP; Wardrop J; Stevenson LF; Bourdon JC; Woods YL; Lane DP
    J Biol Chem; 2004 Oct; 279(40):42169-81. PubMed ID: 15280377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
    Linke K; Mace PD; Smith CA; Vaux DL; Silke J; Day CL
    Cell Death Differ; 2008 May; 15(5):841-8. PubMed ID: 18219319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
    Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
    Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlocking the Mdm2-p53 loop: ubiquitin is the key.
    Clegg HV; Itahana K; Zhang Y
    Cell Cycle; 2008 Feb; 7(3):287-92. PubMed ID: 18235222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.
    Nie J; Xie P; Liu L; Xing G; Chang Z; Yin Y; Tian C; He F; Zhang L
    J Biol Chem; 2010 Jul; 285(30):22818-30. PubMed ID: 20484049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2.
    Singh RK; Iyappan S; Scheffner M
    J Biol Chem; 2007 Apr; 282(15):10901-7. PubMed ID: 17301054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genetic approach to mapping the p53 binding site in the MDM2 protein.
    Freedman DA; Epstein CB; Roth JC; Levine AJ
    Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
    Tian H; Tackmann NR; Jin A; Zheng J; Zhang Y
    J Biol Chem; 2017 Dec; 292(52):21614-21622. PubMed ID: 29123033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
    Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
    Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.